GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » Cash Payments

BioInvent International AB (OSTO:BINV) Cash Payments


View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.


BioInvent International AB (OSTO:BINV) Business Description

Traded in Other Exchanges
Address
Ideongatan 1, The Gamma Building, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.